Abstract
The introduction of inhibitors of signal transduction pathways has increased the therapeutic arsenal for patients with advanced colorectal cancer (ACC). Bevacizumab, a monoclonal vascular endothelial growth factor antibody, is currently part of the standard first-line treatment in combination with fluoropyrimidine-based chemotherapy. Cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor, has shown efficacy in irinotecan-refractory ACC patients. Several experimental targeted agents, including small molecules that inhibit receptor tyrosine kinase activity, are currently being tested. We review the mechanism of action as well as the current status of targeted therapy in ACC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
